
Pinetree Therapeutics Raises $17M to Propel Breakthrough Cancer Therapies with Innovative Protein Degradation Platform
Pinetree Therapeutics, Inc., a trailblazer in targeted protein degradation (TPD) technology, has successfully closed a Series A funding round, raising $17 million to advance its AbReptor™ platform. This investment round was co-led by STIC Investments and DSC Investment, with new participation from Atinum Investment, Quantum FA, and S&S Investment, alongside existing backers DSC Investment, Schmidt,…